These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 28453490)

  • 21. Plasma Amyloid-β dynamics in late-life major depression: a longitudinal study.
    Pomara N; Bruno D; Plaska CR; Ramos-Cejudo J; Osorio RS; Pillai A; Imbimbo BP; Zetterberg H; Blennow K
    Transl Psychiatry; 2022 Jul; 12(1):301. PubMed ID: 35902554
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolism of amyloid-β protein may be affected in depression.
    Baba H; Nakano Y; Maeshima H; Satomura E; Kita Y; Suzuki T; Arai H
    J Clin Psychiatry; 2012 Jan; 73(1):115-20. PubMed ID: 22152118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine.
    Blasko I; Jellinger K; Kemmler G; Krampla W; Jungwirth S; Wichart I; Tragl KH; Fischer P
    Neurobiol Aging; 2008 Jan; 29(1):1-11. PubMed ID: 17055615
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Macrophage Migration Inhibitory Factor is Associated with Biomarkers of Alzheimer's Disease Pathology and Predicts Cognitive Decline in Mild Cognitive Impairment and Mild Dementia.
    Oikonomidi A; Tautvydaitė D; Gholamrezaee MM; Henry H; Bacher M; Popp J
    J Alzheimers Dis; 2017; 60(1):273-281. PubMed ID: 28826184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sleep Deprivation Induced Plasma Amyloid-β Transport Disturbance in Healthy Young Adults.
    Wei M; Zhao B; Huo K; Deng Y; Shang S; Liu J; Li Y; Ma L; Jiang Y; Dang L; Chen C; Wei S; Zhang J; Yang H; Gao F; Qu Q
    J Alzheimers Dis; 2017; 57(3):899-906. PubMed ID: 28304302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amyloid-associated depression and ApoE4 allele: longitudinal follow-up for the development of Alzheimer's disease.
    Qiu WQ; Zhu H; Dean M; Liu Z; Vu L; Fan G; Li H; Mwamburi M; Steffens DC; Au R
    Int J Geriatr Psychiatry; 2016 Mar; 31(3):316-22. PubMed ID: 26250797
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of Midlife Plasma Amyloid-β Levels With Cognitive Impairment in Late Life: The ARIC Neurocognitive Study.
    Sullivan KJ; Blackshear C; Simino J; Tin A; Walker KA; Sharrett AR; Younkin S; Gottesman RF; Mielke MM; Knopman D; Windham BG; Griswold ME; Mosley TH
    Neurology; 2021 Sep; 97(11):e1123-e1131. PubMed ID: 34349010
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Depression, antidepressants, and plasma amyloid beta (Beta) peptides in those elderly who do not have cardiovascular disease.
    Sun X; Mwamburi DM; Bungay K; Prasad J; Yee J; Lin YM; Liu TC; Summergrad P; Folstein M; Qiu WQ
    Biol Psychiatry; 2007 Dec; 62(12):1413-7. PubMed ID: 17544381
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuropsychological Testing Predicts Cerebrospinal Fluid Amyloid-β in Mild Cognitive Impairment.
    Kandel BM; Avants BB; Gee JC; Arnold SE; Wolk DA;
    J Alzheimers Dis; 2015; 46(4):901-12. PubMed ID: 25881908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid-β Concentrations and Cognition Outcomes in Alzheimer's Disease Patients: A Multicenter, Randomized, Controlled Clinical Trial.
    Boada M; Anaya F; Ortiz P; Olazarán J; Shua-Haim JR; Obisesan TO; Hernández I; Muñoz J; Buendia M; Alegret M; Lafuente A; Tárraga L; Núñez L; Torres M; Grifols JR; Ferrer I; Lopez OL; Páez A
    J Alzheimers Dis; 2017; 56(1):129-143. PubMed ID: 27911295
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Depression is associated with low plasma Abeta42 independently of cardiovascular disease in the homebound elderly.
    Qiu WQ; Sun X; Selkoe DJ; Mwamburi DM; Huang T; Bhadela R; Bergethon P; Scott TM; Summergrad P; Wang L; Rosenberg I; Folstein M
    Int J Geriatr Psychiatry; 2007 Jun; 22(6):536-42. PubMed ID: 17096467
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma levels of Abeta42 and Abeta40 in Alzheimer patients during treatment with the acetylcholinesterase inhibitor tacrine.
    Basun H; Nilsberth C; Eckman C; Lannfelt L; Younkin S
    Dement Geriatr Cogn Disord; 2002; 14(3):156-60. PubMed ID: 12218259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of APOE-ɛ4 and beta amyloid in the differential rate of recovery from ECT: a review.
    Sutton TA; Sohrabi HR; Rainey-Smith SR; Bird SM; Weinborn M; Martins RN
    Transl Psychiatry; 2015 Mar; 5(3):e539. PubMed ID: 25826114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The clinical picture of Alzheimer's disease in the decade before diagnosis: clinical and biomarker trajectories.
    Ritchie K; Carrière I; Berr C; Amieva H; Dartigues JF; Ancelin ML; Ritchie CW
    J Clin Psychiatry; 2016 Mar; 77(3):e305-11. PubMed ID: 26891108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
    Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
    J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
    [TBL] [Abstract][Full Text] [Related]  

  • 37. State-dependent alterations in cerebrospinal fluid Aβ42 levels in cognitively intact elderly with late-life major depression.
    Pomara N; Bruno D; Osorio RS; Reichert C; Nierenberg J; Sarreal AS; Hernando RT; Marmar CR; Wisniewski T; Zetterberg H; Blennow K
    Neuroreport; 2016 Sep; 27(14):1068-71. PubMed ID: 27508979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transient increase of plasma concentrations of amyloid β peptides after electroconvulsive therapy.
    Zimmermann R; Schmitt H; Rotter A; Sperling W; Kornhuber J; Lewczuk P
    Brain Stimul; 2012 Jan; 5(1):25-9. PubMed ID: 22037136
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum NGAL is Associated with Distinct Plasma Amyloid-β Peptides According to the Clinical Diagnosis of Dementia in Down Syndrome.
    Naudé PJ; Dekker AD; Coppus AM; Vermeiren Y; Eisel UL; van Duijn CM; Van Dam D; De Deyn PP
    J Alzheimers Dis; 2015; 45(3):733-43. PubMed ID: 25613101
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum amyloid beta protein in young and elderly depression: a pilot study.
    Kita Y; Baba H; Maeshima H; Nakano Y; Suzuki T; Arai H
    Psychogeriatrics; 2009 Dec; 9(4):180-5. PubMed ID: 20377819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.